FOLH1 and posterior cortical atrophy: On the one hand, the performance of these radiolabeled PSMA ligands demonstrate the high potential of a targeted radionuclide therapy for advanced PCa and encourage the theranostic concept that may lead to a substantial improvement in the clinical management of PCa [21].